-
1
-
-
33748761925
-
The burden of HPV-related cancer
-
Parkin M, Bray F. The burden of HPV-related cancer. Vaccine. 2006;24 (Suppl 3):S11-S25.
-
(2006)
Vaccine
, vol.24
, Issue.SUPPL. 3
-
-
Parkin, M.1
Bray, F.2
-
3
-
-
0037421589
-
Epidemiologic classification of human papillomavirus types associated with cervical cancer
-
DOI 10.1056/NEJMoa021641
-
Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.6
, pp. 518-527
-
-
Munoz, N.1
Bosch, F.X.2
De Sanjose, S.3
Herrero, R.4
Castellsague, X.5
Shah, K.V.6
Snijders, P.J.F.7
Meijer, C.J.L.M.8
-
4
-
-
33747892746
-
Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
-
Chapter 4
-
Lacey CJN, Lowndes CM, Shah KV. Chapter 4. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2004;24(Suppl 3):S35-S41.
-
(2004)
Vaccine
, vol.24
, Issue.SUPPL. 3
-
-
Lacey, C.J.N.1
Lowndes, C.M.2
Shah, K.V.3
-
5
-
-
0035919183
-
Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females
-
Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995-3002.
-
(2001)
JAMA
, vol.285
, pp. 2995-3002
-
-
Moscicki, A.B.1
Hills, N.2
Shiboski, S.3
-
6
-
-
0037310596
-
Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students
-
Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-226.
-
(2003)
Am J Epidemiol
, vol.157
, pp. 218-226
-
-
Winer, R.L.1
Lee, S.K.2
Hughes, J.P.3
-
7
-
-
17944387725
-
The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women
-
Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
-
(1998)
J Pediatr
, vol.132
, pp. 277-284
-
-
Moscicki, A.B.1
Shiboski, S.2
Broering, J.3
-
8
-
-
0037077876
-
Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study
-
Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 2002;325:572-574.
-
(2002)
BMJ
, vol.325
, pp. 572-574
-
-
Kjaer, S.K.1
Van Den Brule, A.J.2
Paull, G.3
-
9
-
-
33747891189
-
HPV vaccines in immunocompromised women and men
-
Chapter 16
-
Palefsky JM, Gillison ML, Strickler HD. Chapter 16. HPV vaccines in immunocompromised women and men. Vaccine. 2006;24(Suppl 3): S140-S146.
-
(2006)
Vaccine
, vol.24
, Issue.SUPPL. 3
-
-
Palefsky, J.M.1
Gillison, M.L.2
Strickler, H.D.3
-
10
-
-
3042802290
-
Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: Risk factors and differences, by phylogenetic type
-
Moscicki AB, Ellenberg JH, Farhat S, et al. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis. 2004;190: 37-45.
-
(2004)
J Infect Dis
, vol.190
, pp. 37-45
-
-
Moscicki, A.B.1
Ellenberg, J.H.2
Farhat, S.3
-
11
-
-
4944232942
-
Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents
-
Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis. 2004;190:1413-1421.
-
(2004)
J Infect Dis
, vol.190
, pp. 1413-1421
-
-
Moscicki, A.B.1
Ellenberg, J.H.2
Crowley-Nowick, P.3
-
12
-
-
0037560095
-
Longitudinal study of cervical squamous intraepithelial lesions in human immunodefidency virus (HIV)-seropositive and at-risk HIV-seronegative women
-
DOI 10.1086/375783
-
Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003;188:128-136. (Pubitemid 36829752)
-
(2003)
Journal of Infectious Diseases
, vol.188
, Issue.1
, pp. 128-136
-
-
Schuman, P.1
Ohmit, S.E.2
Klein, R.S.3
Duerr, A.4
Cu-Uvin, S.5
Jamieson, D.J.6
Anderson, J.7
Shah, K.V.8
-
13
-
-
0034692433
-
Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome
-
Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92: 1500-1510.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 1500-1510
-
-
Frisch, M.1
Biggar, R.J.2
Goedert, J.J.3
-
14
-
-
50949116967
-
Incidence and risk factors for verrucae in women
-
Dolev JC, Maurer T, Springer G, et al. Incidence and risk factors for verrucae in women. AIDS. 2008;22:1213-1219.
-
(2008)
AIDS
, vol.22
, pp. 1213-1219
-
-
Dolev, J.C.1
Maurer, T.2
Springer, G.3
-
15
-
-
0036123389
-
Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls
-
De Panfilis G, Melzani G, Mori G, et al. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis. 2002;29:121-125.
-
(2002)
Sex Transm Dis
, vol.29
, pp. 121-125
-
-
De Panfilis, G.1
Melzani, G.2
Mori, G.3
-
16
-
-
34248326338
-
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
-
The Future II Group
-
The Future II Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356: 1915-1927.
-
(2007)
N Engl J Med
, vol.356
, pp. 1915-1927
-
-
-
17
-
-
8444249386
-
Efficacy of a bivalent L1 viruslike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial
-
Harper DM, Franco EI, Wheeler C, et al. Efficacy of a bivalent L1 viruslike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004;364:1757-1765.
-
(2004)
Lancet
, vol.364
, pp. 1757-1765
-
-
Harper, D.M.1
Franco, E.I.2
Wheeler, C.3
-
18
-
-
34248365967
-
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
-
DOI 10.1056/NEJMoa061760
-
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943. (Pubitemid 46740303)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.19
, pp. 1928-1943
-
-
Garland, S.M.1
Hernandez-Avila, M.2
Wheeler, C.M.3
Perez, G.4
Harper, D.M.5
Leodolter, S.6
Tang, G.W.K.7
Ferris, D.G.8
Steben, M.9
Bryan, J.10
Taddeo, F.J.11
Railkar, R.12
Esser, M.T.13
Sings, H.L.14
Nelson, M.15
Boslego, J.16
Sattler, C.17
Barr, E.18
Koutsky, L.A.19
-
19
-
-
34249047002
-
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three clinical trials
-
Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three clinical trials. Lancet. 2007;369: 1693-1702.
-
(2007)
Lancet
, vol.369
, pp. 1693-1702
-
-
Joura, E.A.1
Leodolter, S.2
Hernandez-Avila, M.3
-
20
-
-
34249654115
-
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: A combined analysis of four randomised clinical trials
-
The FUTURE II Study Group
-
The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet. 2007; 369:1861-1868.
-
(2007)
Lancet
, vol.369
, pp. 1861-1868
-
-
-
23
-
-
0037246949
-
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay
-
Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10:108-115.
-
(2003)
Clin Diagn Lab Immunol
, Issue.10
, pp. 108-115
-
-
Opalka, D.1
Lachman, C.E.2
MacMullen, S.A.3
-
24
-
-
27644558808
-
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18
-
Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005;12:959-969.
-
(2005)
Clin Diagn Lab Immunol
, Issue.12
, pp. 959-969
-
-
Dias, D.1
Van Doren, J.2
Schlottmann, S.3
-
25
-
-
33750938518
-
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
-
Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-2145.
-
(2006)
Pediatrics
, Issue.118
, pp. 2135-2145
-
-
Block, S.L.1
Nolan, T.2
Sattler, C.3
-
26
-
-
33847391616
-
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents
-
Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infect Dis J. 2007;26:201-209.
-
(2007)
Pediatr Infect Dis J
, vol.26
, pp. 201-209
-
-
Reisinger, K.S.1
Block, S.L.2
Lazcano-Ponce, E.3
-
27
-
-
77957296730
-
-
Merck & Co., Inc Merck & Co., Inc., Whitehouse Station, NJ
-
Merck & Co., Inc. 2009. GARDASIL product information. Merck & Co., Inc., Whitehouse Station, NJ.
-
(2009)
GARDASIL Product Information
-
-
-
28
-
-
33747892383
-
Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms
-
Chapter 12
-
Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(Suppl 3):S106-S113.
-
(2006)
Vaccine
, vol.24
, Issue.SUPPL. 3
-
-
Stanley, M.1
Lowy, D.R.2
Frazer, I.3
-
29
-
-
49749084695
-
Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature
-
Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol. 2008;110:S1-S10.
-
(2008)
Gynecol Oncol
, vol.110
-
-
Schwarz, T.F.1
Leo, O.2
-
30
-
-
0029610072
-
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
-
Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92:11553-11557.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 11553-11557
-
-
Suzich, J.A.1
Ghim, S.J.2
Palmer-Hill, F.J.3
-
31
-
-
33747892383
-
Prophylactic HPV vaccines: Underlying mechanisms
-
Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(Suppl 3):S106-S113.
-
(2006)
Vaccine
, vol.24
, Issue.SUPPL. 3
-
-
Stanley, M.1
Lowy, D.R.2
Frazer, I.3
-
32
-
-
33845273878
-
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
-
Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
-
(2006)
Br J Cancer
, vol.95
, pp. 1459-1466
-
-
Villa, L.L.1
Costa, R.L.R.2
Petta, C.A.3
-
33
-
-
34249689698
-
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
-
Olsson S-E, Vulla LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931-4939.
-
(2007)
Vaccine
, vol.25
, pp. 4931-4939
-
-
Olsson, S.-E.1
Vulla, L.L.2
Costa, R.L.R.3
-
34
-
-
12844272147
-
Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women
-
Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev. 2005;14:283-288.
-
(2005)
Cancer Epidemiol Biomarkers Prev
, vol.14
, pp. 283-288
-
-
Viscidi, R.P.1
Snyder, B.2
Cu-Uvin, S.3
-
35
-
-
0034908410
-
Immunization of HIV-infected children with varicella vaccine
-
The ACTG 265 Team
-
Levin MJ, Gershon AA, Weinberg A, et al; and the ACTG 265 Team. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310.
-
(2001)
J Pediatr
, vol.139
, pp. 305-310
-
-
Levin, M.J.1
Gershon, A.A.2
Weinberg, A.3
-
36
-
-
47149118319
-
Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children
-
The Infant, Maternal, Pediatric, Adolescent AIDS Clinical Trials P1057 Team
-
Levin MJ, Song L-Y, Fenton T, et al; for the Infant, Maternal, Pediatric, Adolescent AIDS Clinical Trials P1057 Team. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008;26:4210-4217.
-
(2008)
Vaccine
, vol.26
, pp. 4210-4217
-
-
Levin, M.J.1
Song, L.-Y.2
Fenton, T.3
-
37
-
-
46049112339
-
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIVinfected viremic individuals
-
Moir S, Ho J, Malasipina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIVinfected viremic individuals. J Exp Med. 2008;205:1797-1805.
-
(2008)
J Exp Med
, vol.205
, pp. 1797-1805
-
-
Moir, S.1
Ho, J.2
Malasipina, A.3
-
38
-
-
33144461111
-
Appearance of immature/transitional B cells in HIB-infected individuals with advanced disease: Correlation with increased IL-7
-
Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIB-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A 2006;103:2262-2267.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 2262-2267
-
-
Malaspina, A.1
Moir, S.2
Ho, J.3
-
39
-
-
1542283730
-
Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection
-
DeMilito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180-2186.
-
(2004)
Blood
, vol.103
, pp. 2180-2186
-
-
Demilito, A.1
Nilsson, A.2
Titanji, K.3
-
40
-
-
34250176946
-
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease
-
Hart M, Steel A, Clark SA, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol. 2007; 178:8212-8220.
-
(2007)
J Immunol
, vol.178
, pp. 8212-8220
-
-
Hart, M.1
Steel, A.2
Clark, S.A.3
-
41
-
-
49149121468
-
Impaired naïve and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection
-
Jiang W, Lederman MM, Mohner RJ, et al. Impaired naïve and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol. 2008;82:7837-7845.
-
(2008)
J Virol
, vol.82
, pp. 7837-7845
-
-
Jiang, W.1
Lederman, M.M.2
Mohner, R.J.3
-
42
-
-
33749426110
-
Immunogenicity and safety of and predictors of response to a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy (Pediatric AIDS Clinical Trials Group P1024)
-
The P1024 Protocol Team
-
Abzug MJ, Pelton SI, Song L-Y, et al; for the P1024 Protocol Team. Immunogenicity and safety of and predictors of response to a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy (Pediatric AIDS Clinical Trials Group P1024). Pediatr Infect Dis J. 2006;25:920-929.
-
(2006)
Pediatr Infect Dis J
, vol.25
, pp. 920-929
-
-
Abzug, M.J.1
Pelton, S.I.2
Song, L.-Y.3
-
43
-
-
30944454860
-
Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy
-
Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis. 2006;193:302-311.
-
(2006)
J Infect Dis
, vol.193
, pp. 302-311
-
-
Weinberg, A.1
Gona, P.2
Nachman, S.A.3
|